NanoVation Therapeutics

#Cardiometabolic diseases #NanoVation Therapeutics #Novo Nordisk #Partnership #Rare disease

Novo Nordisk and NanoVation enter multi-target partnership

Novo Nordisk and NanoVation Therapeutics have announced a multi-year partnership to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership will combine NanoVation Therapeutics’ long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and… Read More

#Business & Investment #News